Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2010 pubmed 42 citations

Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose-window effect.

Olbrich. Teresa T; Ziegler. Elke E; Türk. Gregor G; Schubert. Antje A; Emons. Günter G; Gründker. Carsten C

Key Findings

  • Kisspeptin‑10 reduces bone‑directed migration of GPR54‑positive breast cancer cells in vitro
  • The anti‑migratory effect occurs only within a specific dose window (10⁻⁹ M to 10⁻¹¹ M)
  • Kisspeptin‑10 lowers CXCR4 expression on cancer cells and decreases SDF‑1 production by bone‑like cells

Practical Outcomes

  • This study suggests kisspeptin‑10 might have anti‑cancer properties, but it’s only been tested in cell cultures, so there’s no safe or effective dosage for people yet. For biohackers, it’s a hint that targeting the CXCR4/SDF‑1 pathway could be worth watching, but it’s not ready for self‑experimentation or clinical use.

Summary

Researchers found that a short peptide called kisspeptin‑10 can block breast cancer cells that have the GPR54 receptor from moving toward bone in lab dishes. The effect only shows up within a narrow concentration range (about one trillionth to one hundred‑billionth of a mole). It works by lowering the cancer cells' CXCR4 receptor and the bone‑cell signal (SDF‑1) that normally attracts them.

Abstract

The KiSS-1 gene product is absent or expressed at low level in metastatic breast cancer compared with their nonmetastatic counterparts. A deca-peptide derived from the KiSS-1 gene product, designated kisspeptin-10 (Kp-10), activates a receptor coupled to Gαq subunits (GPR54 or KiSS-1R). In this study we have analyzed whether Kp-10 treatment affects bone-directed migration of GPR54-positive breast cancer cells. GPR54 expression was analyzed using immune cytochemistry. Bone-directed breast cancer cell invasion was measured by assessment of the breast cancer cell migration rate through an artificial basement membrane. Chemokine receptor CXCR4 and stromal cell-derived factor-1 (SDF-1) mRNA expression was quantified using semi-quantitative RT-PCR. CXCR4 protein expression and SDF-1 protein secretion were measured using the western blot technique. Breast cancer cell invasion was increased when cocultured with MG63 osteoblast-like cells. Treatment with KP-10 reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus. This effect was significant in a dose-window of 10⁻⁹ M to 10⁻¹¹ M. Searching for the molecular mechanisms we found that KP-10 treatment significantly reduces expression of the chemokine receptor CXCR4 by the breast cancer cells. In addition, expression and secretion of its ligand SDF-1 by the MG63 cells were significantly reduced. Furthermore, SDF-1-induced CXCR4 signaling was down-regulated. These data represent the first report that KP-10 inhibits bone-directed migration of GPR54-positive breast cancer cells. In addition, we found evidence for a KP-10 dose-window effect. Furthermore, the SDF-1/CXCR4 system seems to be involved in the anti-migratory action of KP-10.

Study Information

Provider

pubmed

Year

2010

Date

2010-09-15T00:00:00.000Z

DOI

10.1016/j.ygyno.2010.08.018

Citations

42

References

27